Berkshire Hathaway adds Apple and Teva shares, sells IBM stake

By Pouyan Broukhim

Warren Buffett’s Berkshire Hathaway recently disclosed a range of market activity, revealing that it had bought a new stake in Teva Pharmaceutical Industries, purchasing a total 18.9mn shares in the Israeli-based pharmaceutical firm – a stake valued at $365.3mn.

Teva’s shares rose over 10% in after hours trading off the back of the investment.

See also:

Further, the company also became Apple’s largest common stock investor, having upped its holdings in the US tech giant by 31.24mn shares to a total 165.33mn shares compared to the 134.09mn recorded on 31 December, according to data from MarketWatch.

However, whilst Berkshire made new investments, it also ditched its less successful ventures, having sold over 94% of its International Business Machines (IBM) stake. This was originally purchased back in 2011, with Buffett since having admitted that it was one of his bigger investing mistakes.

Additionally, Berkshire also announced that it would be selling more than 43% of oil refiner Phillips 66 in a share repurchase program for approximately $3.3bn.

The investment announcements from Berkshire follow on from the company signing a new partnership with Amazon and JPMorgan Chase & Co. in the aim of creating a new leading healthcare company throughout 2018.


Featured Articles

DEI done right: Brook Sims, COO, MAC Diversity Recruiters

Passionate about helping others find their voice, diversity leader and COO Brook Sims talks powerful leadership, diverse teams and being a change agent

Q&A: China’s ecommerce innovator Jeff Li, CEO of Shoplazza

Named in Fortune China’s 40 under 40 for 2022, former Baidu head Jeff Li is the entrepreneurial founder and CEO of ecommerce platform Shoplazza

How hybrid work is revolutionising the physical office

As hybrid work models roll out worldwide, the purpose of the office is changing with collaboration, connection and networking taking centre stage

Trailblazer: Shanique Bonelli-Moore, DEI chief at Clorox


Dean Forbes – the Forterro CEO aiming for the moon

Leadership & Strategy

Why becoming a B Corp is good for business